The scope of this report is to detect patterns of patenting activity and innovation in the area of vaccine research and manufacturing in order to facilitate the sourcing of vaccine technologies that could potentially be used in developing countries. Part I provides an overview of patenting activity in the area of vaccines by means of a statistical analysis. Part II focuses on the patenting related to vaccines for: streptococcus pneumonia conjugate vaccines; typhoid conjugate vaccines; and influenza vaccines. Each part of the report also includes a special focus on the patenting activity in Brazil, China and India.

Since the start of the COVID-19 pandemic there have been remarkable research and innovation efforts to fight the SARS-COV-2 virus and the related disease. This patent landscape report provides early observations on the patenting activity which took place in the field of COVID-19 vaccines and therapeutics, and compares results with clinical trial data for related candidate vaccines and drugs.

These Guidelines are designed both for general users of patent information, as well as for those involved in producing Patent Landscape Reports (PLRs). They provide step-by-step instructions on how to prepare a PLR, as well as background information such as objectives, patent analytics, concepts and frameworks.

The seventh edition of the Canadian Immunization Guide was developed by the National Advisory Committee on Immunization (NACI), with the support ofthe Immunization and Respiratory Infections Division, Public Health Agency of Canada, to provide updated information and recommendations on the use of vaccines in Canada. The Public Health Agency of Canada conducted a survey in 2004, which confi rmed that the Canadian Immunization Guide is a very useful and reliable resource of information on immunization.

Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.

Vaccination is a fundamental component of preventive medicine and public health. The use of vaccines to prevent infectious diseases has resulted in dramatic decreases in disease, disability, and death in the United States and around the world. The current political, economic, and social environment presents both opportunities for and challenges to strengthening the U.S. system for developing, manufacturing, regulating, distributing, funding, and administering safe and effective vaccines for all people. Priorities for the National Vaccine Plan examines the extraordinarily complex vaccine enterprise, from research and development of new vaccines to financing and reimbursement of immunization services. Priorities for the National Vaccine Plan examines the extraordinarily complex vaccine enterprise, from research and development of new vaccines to financing and reimbursement of immunization services. The book makes recommendations about priority actions in the update to the National Vaccine Plan that are intended to achieve the objectives of disease prevention and enhancement of vaccine safety. It is centered on the plan's five goals in the areas of vaccine development, safety, communication, supply and use, and global health.

This report aims to provide patent based information on available technologies and patenting trends in the area of microalgae. It covers in detail patent applications and granted patents within the space of microalgae and has revealed several interesting facets of research and innovation related to that area. Expected to be the 3rd generation biofuels solution, microalgae have quickly been developed for the biofuel industry with a marked inflection point in 2006. Lipids and pigments, which are the second metabolites of interest, also developed early on, still continue to see a steady growth in recent years.